Table 5 Multivariate analyses of... | American Society of Hematology

Table 5

Multivariate analyses of survival, leukemia-free survival, treatment-related mortality, and relapse in patients undergoing transplantation for advanced phase chronic myeloid leukemia

Variable	n	Relative risk of death (95% CI)	P
Survival
Main effect
No imatinib	216	1.00*
Imatinib	216	0.93 (0.74-1.18)	.570†
Leukemia-free survival
Main effect
No imatinib	216	1.00*
Imatinib	216	1.05 (0.84-1.32)	.670†
Treatment-related mortality
Main effect
No imatinib	216	1.00*
Imatinib	216	0.87 (0.64-1.18)	.350†
Other significant covariates
Karnofsky score at transplantation			.007‡
> 80%	276	1.00*
≤ 80%	122	1.67 (1.21-2.31)	.002
Unknown	34	1.08 (0.60-1.94)	.790
Relapse
Main effect
No imatinib	216	1.00*
Imatinib	216	1.35 (0.95-1.89)	.090†

Variable	n	Relative risk of death (95% CI)	P
Survival
Main effect
No imatinib	216	1.00*
Imatinib	216	0.93 (0.74-1.18)	.570†
Leukemia-free survival
Main effect
No imatinib	216	1.00*
Imatinib	216	1.05 (0.84-1.32)	.670†
Treatment-related mortality
Main effect
No imatinib	216	1.00*
Imatinib	216	0.87 (0.64-1.18)	.350†
Other significant covariates
Karnofsky score at transplantation			.007‡
> 80%	276	1.00*
≤ 80%	122	1.67 (1.21-2.31)	.002
Unknown	34	1.08 (0.60-1.94)	.790
Relapse
Main effect
No imatinib	216	1.00*
Imatinib	216	1.35 (0.95-1.89)	.090†

Reference group.

†

One degree of freedom.

‡

Two degrees of freedom.

View Large

This Feature Is Available To Subscribers Only